Brain Response to an Intervention Using Guided, At-Home Technology for the Mind
BRIGHT-Mind
1 other identifier
interventional
817
1 country
1
Brief Summary
The objective of this study is to assess the effectiveness of two digital programs for providing mental stimulation, improving cognition, and inducing changes in brain structure and function.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jul 2023
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 8, 2023
CompletedFirst Posted
Study publicly available on registry
June 22, 2023
CompletedStudy Start
First participant enrolled
July 5, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 11, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
March 11, 2025
CompletedJuly 30, 2026
July 1, 2026
1.7 years
June 8, 2023
July 29, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Overall Composite from Creyos (formerly Cambridge Brain Sciences)
The Overall Composite is derived from the 12 tests in the Creyos battery.
Study Day 0 to Study Day 84
Secondary Outcomes (7)
Concentration Domain Score from Creyos
Study Day 0 to Study Day 84
Memory Domain Score from Creyos
Study Day 0 to Study Day 84
Planning Domain Score from Creyos
Study Day 0 to Study Day 84
Reasoning Domain Score from Creyos
Study Day 0 to Study Day 84
Structural Brain Composite from Magnetic Resonance Imaging (MRI)
Study Day 0 to Study Day 84
- +2 more secondary outcomes
Study Arms (2)
Cohort A
OTHERRemote-Only subjects
Cohort B
OTHERRemote + Imaging subjects
Interventions
2/3 of randomized subjects use digital program 1 for 12 weeks to provide mental stimulation
1/3 of randomized subjects use digital program 2 for 12 weeks to provide mental stimulation
Eligibility Criteria
You may qualify if:
- Subjects 25-80 years of age.
- Ability to understand and speak English, follow written and verbal instructions (English), and give informed consent (English), as assessed by study staff.
- Ability to comply with all the testing and study requirements, including the ability to independently use a video conferencing tool and the ability to independently use a computer to access the web.
- Ability to independently complete a daily, online intervention and outcome assessments using a web browser compatible with the intervention and assessment software on a reliable, internet-connected laptop or desktop computer.
You may not qualify if:
- Current, controlled (requiring treatment) or uncontrolled psychiatric diagnosis, including but not limited to posttraumatic stress disorder, psychosis, bipolar illness, pervasive developmental disorder, severe obsessive compulsive disorder, severe depressive or severe anxiety disorder, conduct disorder, attention-deficit/hyperactivity disorder, or other symptomatic manifestations that in the opinion of the Investigator may confound study data/assessments.
- Current, controlled (requiring treatment) or uncontrolled neurological diagnosis, including but not limited to Alzheimer's Disease, other dementias, mild cognitive impairment, Huntington's Disease, Parkinson's Disease, multiple sclerosis, stroke, epilepsy, aphasia, or other condition that in the opinion of the Investigator may confound study data/assessments.
- Any other medical condition in the last 90 days that in the opinion of the Investigator may confound study data/assessments.
- Has been under the care of a caretaker or has not been living independently in the last 90 days.
- In the last three years has used any of the following for more than two weeks continuously: Online courses, Online brain training programs
- Known sensitivity (such as headaches, dizziness, nausea) to bright, stimulating video displays.
- History of seizures (excluding febrile seizures), or significant motor or vocal tics, including but not limited to Tourette's Disorder and photo-sensitive epilepsy.
- Visual acuity that cannot be corrected that prevents or negatively impacts computer activity.
- Has participated in a clinical trial within 90 days prior to screening.
- Pregnancy or planning to become pregnant.
- Unwillingness or inability to comply with imaging safety protocols.
- Metal implants or exposure to shrapnel.
- Left-handed or ambidextrous.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Lumos Labs, Inc.lead
Study Sites (1)
Lumos Labs, Inc.
San Francisco, California, 94108, United States
Study Officials
- PRINCIPAL INVESTIGATOR
Kevin Madore, PhD
Lumos Labs, Inc.
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 8, 2023
First Posted
June 22, 2023
Study Start
July 5, 2023
Primary Completion
March 11, 2025
Study Completion
March 11, 2025
Last Updated
July 30, 2026
Record last verified: 2026-07
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP
- Time Frame
- Concurrent with the publication of a research article with no anticipated end date.
- Access Criteria
- Qualified investigators for noncommercial research purposes, upon reasonable request to the corresponding author and approval by Lumos Labs, Inc., with a signed data use agreement.
Deidentified individual participant data underlying the results reported in a peer-reviewed research article will be made available.